Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

• Status: Completed
• Trial end date: 2007-05-01

Summary

The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety

• Phase: Phase 3

Details

• Lead Sponsor: Abbott
• Treatments: Adalimumab; Antibodies; Antibodies, Monoclonal; Infliximab